FDA Approval Summary: Belzutifan for VHL Disease Tumors-Letter

Jonathan Q. Trinh; Moataz Ellithi; Nicole Shonka; Raymond C. Bergan

doi:10.1158/1078-0432.CCR-22-2968

FDA Approval Summary: Belzutifan for VHL Disease Tumors-Letter

Jonathan Q. Trinh, Moataz Ellithi, Nicole Shonka, Raymond C. Bergan

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	684
Number of pages	1
Journal	Clinical cancer research : an official journal of the American Association for Cancer Research
Volume	29
Issue number	3
DOIs	https://doi.org/10.1158/1078-0432.CCR-22-2968
State	Published - Feb 1 2023

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-22-2968

Cite this

@article{345fad623708431d9e5c189cbb569bba,

title = "FDA Approval Summary: Belzutifan for VHL Disease Tumors-Letter",

author = "Trinh, {Jonathan Q.} and Moataz Ellithi and Nicole Shonka and Bergan, {Raymond C.}",

year = "2023",

month = feb,

day = "1",

doi = "10.1158/1078-0432.CCR-22-2968",

language = "English (US)",

volume = "29",

pages = "684",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "3",

}

TY - JOUR

T1 - FDA Approval Summary

T2 - Belzutifan for VHL Disease Tumors-Letter

AU - Trinh, Jonathan Q.

AU - Ellithi, Moataz

AU - Shonka, Nicole

AU - Bergan, Raymond C.

PY - 2023/2/1

Y1 - 2023/2/1

UR - http://www.scopus.com/inward/record.url?scp=85147187126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147187126&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-22-2968

DO - 10.1158/1078-0432.CCR-22-2968

M3 - Article

C2 - 36722140

AN - SCOPUS:85147187126

SN - 1078-0432

VL - 29

SP - 684

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 3

ER -

FDA Approval Summary: Belzutifan for VHL Disease Tumors-Letter

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this